WHAT YOU SHOULD KNOW ABOUT PAXLOVID AND LONG COVID

/0 Comments/in /by

 

Research findings says people who took Paxlovid are less likely to have long COVID symptoms. The article was published in March 2023 in JAMA Internal Medicine. It revealed that high-risk patients who took Paxlovid within five days of confirming infection for COVID-19 were 26% less likely to have Long COVID symptoms after 90 days, compared to people who weren’t treated. 

 

Long COVID are myriad of symptoms experienced by people after recovering from COVID-19. The study followed through on more than 35,000 patients who took Paxlovid for a six month period. This research was of great importance as the medical community debates what causes Long COVID, and contributes to the understanding of the symptoms and possible causes.

 

Dr. Ziyad Al-Aly, a clinical epidemiologist at the Washington University School of Medicine in St. Louis and co-author of the JAMA study on Paxlovid, said: ” Despite the unknowns, certain patients may want to pursue Paxlovid prescriptions. For people at high risk of severe COVID-19, who already stand to benefit from Paxlovid, the possibility of preventing Long COVID is an added bonus.”

 

For more information on the JAMA study on Paxlovid visit here.

For information and assistance on how to get Paxlovid please call +2348160962414 or visit here.

WHAT YOU SHOULD KNOW ABOUT PAXLOVID APPROVAL

/0 Comments/in /by

   Jennifer Lorenzini/Reuters

 

The U.S Food and Drug Administration (FDA) approves Paxlovid for the treatment of mild-to-moderate COVID-19. In a press release On May 25, 2023, the FDA granted Pfizer approval for its antiviral medication for the treatment of mild-to-moderate COVID-19 in adults who are at high risk for progression to severe COVID-19, including hospitalization or death. The decision means the medication met regulatory safety and efficacy standards, and allows the Pfizer’s drug to remain on the market indefinitely.

 

Paxlovid is an important medication for the treatment of mild-to-moderate coronavirus in adults older than 50 and people with certain underlying medical conditions like diabetes, heart conditions, cancer or a weak immune system, amongst others. The data showed that Paxlovid significantly reduced the proportion of people with COVID-19 related hospitalization or death from any cause through 28 days of follow-up by 86% compared to placebo among patients treated within five days of symptom onset and who did not receive COVID-19 therapeutic monoclonal antibody treatment. In this analysis, 977 patients received Paxlovid, and 989 patients received placebo, and among these patients, 0.9% who received Paxlovid were hospitalized due to COVID-19 or died from any cause during 28 days of follow-up compared to 6.5% of the patients who received the placebo.

 

Dr. Patrizia Cavazzoni, director for the FDA’s Center for Drug Evaluation and Research, said: ”Today’s approval demonstrates that Paxlovid has met the agency’s rigorous standards for safety and effectiveness, and that it remains an important treatment option for people at high risk for progression to severe COVID-19, including those with prior immunity.”

 

For further information on Paxlovid FDA approval visit here.

For information and assistance on how to get Paxlovid please call +2348160962414 or visit here.

PAXLOVID: LOWER RISK OF SEVERE COVID IN PATIENTS WITH UNDERLYING CHRONIC CONDITIONS

/0 Comments/in /by

 

Paxlovid reduces risk of severe COVID-19 in patients with chronic health condition a new study finds. The study which was conducted by researchers at Harvard University was published in June 2023 in the Clinical Infectious Diseases Journal. This investigation will contribute to proper use of the antiviral medication in the treatment of patients in the most cost effective manner.

 

This study is important because as governments funding for COVID-19 treatment reduces, cost of the medication is likely to increase. This means Clinicians need correct information on cost effective means to treat COVID-19, prescribing antiviral medications for those who need them the most. The study was needed because the effect of Paxlovid on COVID-19 outcomes in younger vaccinated adults are unclear.

 

Researchers in the study assessed outcomes among two groups of 2,547 COVID-19 patients aged 18 to 50 years. Paxlovid was linked to a 30% lower risk of all-cause emergency department visits, hospitalization, and death among vaccinated, non-hospitalized COVID-19 patients with serious chronic conditions. In addition, Paxlovid recipients had lower rates of constitutional, cardiovascular, and respiratory symptoms than controls.

 

For further information on the findings of this study visit here.

To get assistance on how to get Paxlovid please call +2348160962414 or visit here

 

3 THINGS YOU SHOULD KNOW ABOUT PAXLOVID

/0 Comments/in /by

 

Paxlovid is an oral antiviral medication for the treatment of COVID-19. It was developed by Pfizer for the treatment of mild-to-moderate COVID-19 in adults at high risk for severe disease, including hospitalization and death. The Food and Drug Administration (FDA) first made Paxlovid available in December 2021 under emergency use authorization for high-risk individuals ages 12 and above. Paxlovid is a very important drug to save the lives of people infected by COVID-19. Here are three things you should know about Paxlovid.

When should you take Paxlovid ?

You should take the medication within five days of developing COVID-19 symptoms. This is because once you’ve been sick due to the virus for more than a week, the medications won’t be able to restore the damages the virus must have caused to your body.

How long should you take Paxlovid ?

The medication should be taken for a duration of five days. Your healthcare provider will recommend you take three Paxlovid pills every 12 hours for five days to get the full benefit of the medication.

Where can you get Paxlovid ?

You should be able to get the medication from your hospital or neighborhood pharmacy. However, due to scarcity of the medication only few healthcare facilities might have it available at the time when it is urgently needed.

For further information on how to get Paxlovid please contact us on 08160962414 or visit here for assistance.